Around 30% of people aged 65 and above have diabetes in the United States, according to the American Diabetes Association. Diabetes patients experience a greater risk of developing dementia as compared to people without diabetes. A study has shown that Type 1 diabetics are 93% more likely to be affected by dementia. Thus, the rising burden of diabetes and its association with dementia is augmenting the need for treatments that can address both conditions. This growing demand is likely to lead to significant investments in expanding the drug pipeline and manufacturing capacities.
The Dementia with Diabetes Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into dementia with diabetes drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for dementia with diabetes. The dementia with diabetes report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The dementia with diabetes pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with dementia with diabetes treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to dementia with diabetes.
Diabetes is considered a major risk factor for dementia, which is stimulating the development of novel dementia with diabetes therapeutics. It is reported that type 2 diabetes patients are prone to developing dementia, particularly vascular dementia. Studies have shown that low blood sugar level or hypoglycemia is linked to brain cell degeneration and cognitive decline whereas high blood sugar levels are associated with Alzheimer's disease.
For the management of diabetes in individuals with dementia, some diabetes drugs can help slow the progression of dementia and enhance cognitive function. In some studies, metformin is reported to decrease the risk of memory and thinking problems. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, used primarily for type 2 diabetes, may also reduce the risk of dementia. With substantial investments by pharmaceutical companies, adherence to dementia with diabetes treatment guidelines, and the growing focus on targeted therapies, the drug pipeline is expected to expand in the coming years.
Recent epidemiological studies have suggested the increasing prevalence and incidence of dementia in diabetes patients. Several meta-analyses have estimated that diabetes increases the risk of dementia by nearly half among the patient population.
According to a study published in Diabetes Care (2024), people diagnosed with diabetes in middle age have a higher lifetime risk of dementia (36%) compared to those diagnosed later in life (31%). By age 80, the dementia incidence is also higher in middle age-onset diabetes cases (16.1%) compared to those without diabetes (9.4%). Moreover, dementia tends to appear 4 years earlier for people with middle age-onset diabetes compared to those without diabetes.
This section of the report covers the analysis of dementia with diabetes drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with a substantial number of dementia with diabetes emerging drugs.
The drug molecule categories covered under dementia with diabetes pipeline analysis include proteins and peptides, small molecules, hormones, and enzymes. The dementia with diabetes report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for dementia with diabetes.
The EMR report for dementia with diabetes drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed dementia with diabetes therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in dementia with diabetes clinical trials:
Major drugs currently in the drug pipeline are as follows:
The objective of this multicenter randomized double-blind controlled clinical study is to evaluate the efficacy and safety of dementia with diabetes drug candidate Ginkgo biloba ketone ester tablets, containing extracts of Ginkgo biloba leaves, for the treatment of diabetes related dementia in type 2 diabetes patients with mild cognitive impairment. The study is under Phase IV clinical development and has an estimated 370 participants.
This Phase II clinical study is aimed at examining the efficacy, tolerability, and safety of stem cell therapy...
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The Dementia with Diabetes Drug Report provides a strategic overview of the latest and future landscape of treatments for dementia with diabetes. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within dementia with diabetes pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share